Edwards Lifesciences Corporation (EW) has a MoatMap StockRank of 83/100 based on Quality (77/100), Value (23/100), and Momentum (67/100) factor scores. The current signal is STRONG BUY. Edwards Lifesciences is a high-quality medical device company with a strong moat in TAVR. However, it lacks a direct catalyst or alignment with our 18-month macro themes, and its valuation remains rich.
Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. The company's competitive moat is its proprietary technologies in heart valves and hemodynamic monitoring, strong intellectual property, and extensive clinical evidence supporting its innovative products. Edwards Lifesciences is a market leader in transcatheter aortic valve replacement (TAVR) and advanced hemodynamic monitoring, benefiting from a highly specialized and growing medical device market.
| Price | $87.54 |
| Market Cap | $49.5B |
| P/E (TTM) | 47.27 |
| P/E (Forward) | 25.97 |
| Price/Book | 4.89 |
| Return on Equity | 10.5% |
| Return on Invested Capital | 10.9% |
| Debt/Equity | 6.81 |
| Gross Margin | 77.9% |
| Operating Margin | 31.2% |
| Revenue Growth | 16.7% |
| Free Cash Flow | $902M |
Edwards Lifesciences Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).